Study #2021-0928
Neoadjuvant PD-1 plus TIGIT Blockade in patients with Cisplatin-Ineligible Operable high-risk Urothelial Carcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Atezolizumab, Tiragolumab
Description
To learn if the combination of atezolizumab and tiragolumab can help to control bladder cancer when it is given before surgery to remove the bladder and tumor.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Malignancy
Study phase:
Physician name:
Padmanee Sharma
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.